Get to know our clinical trials

Phase 2 clinical trial to evaluate the safety and efficacy of multiple treatment combinations with telisotuzumab adizutecan in participants with metastatic colorectal cancer.

THE PRIMARY OBJECTIVE IS TO EVALUATE THE EFFICACY OF TELISOTUZUMAB ADIZUTECAN COMBINATIONS COMPARED WITH STANDARD TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC).

Dr. Ignacio Matos, especialista en Oncología Médica, dedicado al diagnóstico y tratamiento del cáncer – Clínica Universidad de Navarra
Dr. Ignacio Matos Curriculum
Specialist Medical Oncology Department
Madrid headquarters
Cancer Center
Gastrointestinal Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • PHASE 2, OPEN-LABEL, RANDOMIZED MASTER PROTOCOL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MULTIPLE TREATMENT COMBINATIONS WITH TELISOTUZUMAB ADIZUTECAN IN PARTICIPANTS WITH METASTATIC COLORECTAL CANCER (ANDROMETA-CRC-533).
  • Code EudraCT: 2024-512981-33-00
  • Protocol number: M24-533
  • Promoter: Abbvie farmacéutica
  • Molecule/Drug: Telisotuzumab Adizutecan (ABBV-400)
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION